Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fluad H5N1 Pandemic Influenza Vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | ACTIVE_COMPARATOR | Primed subject with pandemic Vaccine |
| Group 2 | ACTIVE_COMPARATOR | Non Primed subject with pandemic Vaccine |
| Name | Type | Description |
|---|---|---|
| Fluad H5N1 Pandemic Influenza Vaccine | BIOLOGICAL | Two 0.5 mL doses of MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) hemagglutinin (HA) subvirion influenza vaccine, containing 7.5 μg of H5N1 antigen,administered 3 weeks apart, IM in the deltoid muscle, preferably of the non-dominant arm. |
Inclusion Criteria: 1. Subjects aged 18 to 65 years of age, mentally competent, who have signed an informed consent form after having received a detailed explanation of the study protocol; 2. In good health as determined by: 1. medical history, 2. physical examination, 3. clinical judgmen...
Fluad H5N1 Pandemic Influenza Vaccine is used for the prophylaxis of avian influenza, also known as bird flu. It is an investigational vaccine being developed to prevent infection with the H5N1 influenza virus. The vaccine is intended for use in adults and is currently in clinical development.
Fluad H5N1 Pandemic Influenza Vaccine is being developed by Novartis AG, a multinational pharmaceutical company. Novartis is listed on the stock exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the safety and immunogenicity of this pandemic influenza vaccine.
Fluad H5N1 Pandemic Influenza Vaccine is in Phase 2 clinical development. It is an investigational vaccine and has not yet been approved by regulatory authorities. The vaccine is being studied for its safety and ability to generate an immune response against the H5N1 avian influenza virus.
Fluad H5N1 Pandemic Influenza Vaccine has been studied in one completed Phase 2 clinical trial with the identifier NCT00478816. This trial evaluated the safety and immunogenicity of two doses of the H5N1 influenza vaccine in adults who were either unprimed or primed with adjuvanted or non-adjuvanted influenza vaccines. The study enrolled 58 participants in the United Kingdom.
Fluad H5N1 Pandemic Influenza Vaccine targets the H5N1 strain of the influenza virus, which is a subtype of avian influenza. The vaccine is designed to stimulate the immune system to produce antibodies against this specific virus strain, providing protection against infection. It is being developed as a preventive measure for pandemic preparedness.
Fluad H5N1 Pandemic Influenza Vaccine is a specific vaccine developed for the H5N1 avian influenza virus, distinct from seasonal influenza vaccines. It is an investigational product and not the same as the standard Fluad vaccine used for seasonal flu. The vaccine is being evaluated for its potential use in a pandemic scenario.